Trials / Completed
CompletedNCT03901755
An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B
A 24-month Prospective, Non-interventional, International, Multicentre Study to Describe the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 151 (actual)
- Sponsor
- Swedish Orphan Biovitrum · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Alprolix (rFIXFc) is a recombinant extended half-life coagulation factor product. The purpose of this non-interventional study is to describe the real-world usage and effectiveness of Alprolix in the on-demand and prophylactic treatment of haemophilia B.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alprolix | Extended half-life factor IX product |
Timeline
- Start date
- 2019-09-12
- Primary completion
- 2024-03-12
- Completion
- 2024-03-12
- First posted
- 2019-04-03
- Last updated
- 2025-09-29
Locations
29 sites across 9 countries: Czechia, Greece, Ireland, Italy, Norway, Saudi Arabia, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT03901755. Inclusion in this directory is not an endorsement.